SEC Form SC 13G/A filed by Intellia Therapeutics Inc. (Amendment)

$NTLA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $NTLA alert in real time by email
SC 13G/A 1 tm226027d2_sc13ga.htm SCHEDULE 13G/A

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

 
 

Under the Securities Exchange Act of 1934

 

 
  (Amendment No. 1)*  

 

Intellia Therapeutics, Inc.
(Name of Issuer)

 

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

 

45826J105
(CUSIP Number)

 

December 31, 2021
(Date of Event which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

 

xRule 13d-1(c)

 

¨Rule 13d-1(d)

 

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

1

Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only)

 

REGENERON PHARMACEUTICALS, INC.

 

13-3444607

 

2 Check the Appropriate Box if a Member of a Group (See Instructions)
  (a)    ¨
  (b)    ¨
3 SEC Use Only
4

Citizenship or Place of Organization.

 

New York

 

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

5    Sole Voting Power

 

3,702,995 shares

6    Shared Voting Power

 

0 shares

7    Sole Dispositive Power

 

3,702,995 shares

8    Shared Dispositive Power

 

0 shares

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,702,995 shares

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

¨

11

Percent of Class Represented by Amount in Row (9)

 

4.98% *

 

12

Type of Reporting Person (See Instructions)

 

CO (Corporation)

 

* The percentages reported herein with respect to the Reporting Person’s holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 4, 2021, that as of October 29, 2021, the Issuer had 74,419,414 shares of its common stock, $0.0001 par value per share, outstanding.

 

 

 

 

Item 1. 

 

  (a) Name of Issuer  
   

Intellia Therapeutics, Inc.

 

  (b) Address of Issuer’s Principal Executive Offices
   

40 Erie Street, Suite 130

Cambridge, MA 02139

 

Item 2. 

 

  (a) Name of Person Filing
    Regeneron Pharmaceuticals, Inc.

  (b) Address of Principal Business Office or, if none, Residence
   

777 Old Saw Mill River Road,

Tarrytown, NY 10591

 

  (c) Citizenship
   

 

New York

 

  (d) Title of Class of Securities
   

Common Stock, par value $0.0001 per share

 

  (e) CUSIP Number
    45826J105

 

 

 

 

Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

Item 4.Ownership

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a) Amount Beneficially Owned
     
    3,702,995
     
  (b) Percent of Class
   

 

4.98% *

 

  (c)

Number of shares as to which such person has:

 

    (i) sole power to vote or to direct the vote
     
3,702,995
    (ii) shared power to vote or to direct the vote
     

 

0

 

    (iii) sole power to dispose or to direct the disposition of
     
3,702,995
    (iv) shared power to dispose or to direct the disposition of
     

 

0

 

* The percentages reported herein with respect to the Reporting Person’s holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 4, 2021, that as of October 29, 2021, the Issuer had 74,419,414 shares of its common stock, $0.0001 par value per share, outstanding.

 

Item 5.Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person

 

Not applicable.

 

 

 

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group

 

Not applicable.

 

Item 9.Notice of Dissolution of Group

 

Not applicable.

 

Item 10.Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

ExhibitsExhibit

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

 

February 11, 2022

 

  REGENERON PHARMACEUTICALS, INC.
     
     
  By:  /s/ Leonard N. Brooks
     
  Leonard N. Brooks
  Vice President, Treasurer

 

 

 

Get the next $NTLA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NTLA

DatePrice TargetRatingAnalyst
3/5/2025$30.00Buy
H.C. Wainwright
2/28/2025$45.00 → $13.00Overweight → Neutral
Analyst
2/28/2025$9.00Neutral → Sell
Goldman
1/27/2025$56.00 → $11.00Overweight → Equal-Weight
Morgan Stanley
2/23/2024$136.00 → $32.00Buy → Neutral
Goldman
2/15/2024Peer Perform
Wolfe Research
4/13/2023$66.00Buy
Canaccord Genuity
3/21/2023$54.00Outperform
Bernstein
More analyst ratings

$NTLA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

    CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM). "This is a meaningful step forward in our efforts to accelerate the development of nex-z to bring this potentially transformative treatment to patients as quickly as possible," said Intellia President and Chief Ex

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on March 1, 2025, it awarded an inducement grant to eleven new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units ("RSUs") for 32,600 shares of Intellia's common stock, with one-third of such RSUs vesting on March 1, 2026, 2027 and 2028. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Intellia

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

    Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year endActively screening for the Phase 3 MAGNITUDE-2 trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy; on track to dose first patient in 1Q25En

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$NTLA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NTLA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NTLA
SEC Filings

See more

$NTLA
Leadership Updates

Live Leadership Updates

See more
  • Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

    Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

    Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

    - Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$NTLA
Financials

Live finance-specific insights

See more
  • Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

    Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026 to support plans for U.S. launch in 2027Enrollment in the pivotal Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis (ATTR) with cardiomyopathy continues to track ahead of projections; more than 550 total patients expected to be enrolled by year endActively screening for the Phase 3 MAGNITUDE-2 trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy; on track to dose first patient in 1Q25En

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

    CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2024 financial results and operational highlights in a conference call on February 27, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call wi

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

    Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-endStrong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans Plan to present new clinical data from the ongoing nex-z Phase 1 study at upcoming 2024 American Heart Association Scientific SessionsActively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE) Reported positive results from the Phase 2 study supporting NTLA-2002's potential to be a fun

    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$NTLA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more